Clinical Trial Results: Recent discussions on social media about Zenas BioPharma (ZBIO) have centered on the company’s Phase 3 INDIGO trial results for obexelimab, which showed a significant reduction in flare risk for a rare autoimmune disease. Many users are debating the unexpected 52% stock drop despite the positive data, with some pointing to broader market concerns or company-specific risks.
CEO Stock Purchase: Another hot topic is the recent purchase of $1.63 million in ZBIO shares by the CEO, sparking curiosity among online commentators. While some see this as a strong vote of confidence in the company’s future, others question the timing amidst the stock’s sharp decline. This move has fueled polarized opinions across platforms.
Note: This discussion summary was generated from an AI condensation of post data.
Zenas BioPharma Insider Trading Activity
Zenas BioPharma insiders have traded $ZBIO stock on the open market 11 times in the past 6 months. Of those trades, 11 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ZBIO stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT purchased 316,219 shares for an estimated $6,008,161
- HONGBO LU purchased 263,160 shares for an estimated $5,000,040
- LEON O JR MOULDER (Chief Executive Officer) has made 4 purchases buying 136,928 shares for an estimated $2,408,948 and 0 sales.
- ONE CAPITAL MANAGEMENT, LLC SR has made 2 purchases buying 126,315 shares for an estimated $2,399,985 and 0 sales.
- PATRICK G ENRIGHT has made 2 purchases buying 117,255 shares for an estimated $2,250,026 and 0 sales.
- JASON RALEIGH NUNN purchased 63,158 shares for an estimated $1,200,002
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Zenas BioPharma Hedge Fund Activity
We have seen 31 institutional investors add shares of Zenas BioPharma stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 1,496,836 shares (+45.0%) to their portfolio in Q3 2025, for an estimated $33,229,759
- CITADEL ADVISORS LLC removed 293,785 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $6,522,027
- ARROWMARK COLORADO HOLDINGS LLC removed 269,670 shares (-24.6%) from their portfolio in Q3 2025, for an estimated $5,986,674
- NOVO HOLDINGS A/S removed 250,000 shares (-11.1%) from their portfolio in Q3 2025, for an estimated $5,550,000
- CATALIO CAPITAL MANAGEMENT, LP removed 215,314 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $4,779,970
- VANGUARD GROUP INC added 170,546 shares (+17.2%) to their portfolio in Q3 2025, for an estimated $3,786,121
- EVERSEPT PARTNERS, LP removed 166,737 shares (-51.2%) from their portfolio in Q3 2025, for an estimated $3,701,561
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Zenas BioPharma Analyst Ratings
Wall Street analysts have issued reports on $ZBIO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 12/22/2025
- Evercore ISI Group issued a "Outperform" rating on 11/26/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/28/2025
To track analyst ratings and price targets for Zenas BioPharma, check out Quiver Quantitative's $ZBIO forecast page.
Zenas BioPharma Price Targets
Multiple analysts have issued price targets for $ZBIO recently. We have seen 6 analysts offer price targets for $ZBIO in the last 6 months, with a median target of $44.5.
Here are some recent targets:
- Judah Frommer from Morgan Stanley set a target price of $19.0 on 01/06/2026
- Martin Fan from Wedbush set a target price of $45.0 on 12/22/2025
- Cory Kasimov from Evercore ISI Group set a target price of $55.0 on 11/26/2025
- Matthew Caufield from HC Wainwright & Co. set a target price of $44.0 on 10/28/2025
- Yigal Nochomovitz from Citigroup set a target price of $46.0 on 10/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
